Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.41 |
| ▸ | RORC | P51449 | 4/20 | 0.39 |
| ▸ | XIAP | P98170 | 2/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.34 |
| ▸ | SCARB1 | Q8WTV0 | 2/20 | 0.34 |
| ▸ | CCR3 | P51677 | 2/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | CCKAR | P32238 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1878655 | 0.89 | PTGDR2 (0.40) | PTGDR2RORCXIAPMTNR1AMTNR1B | |
| SCHEMBL14625190 | 0.89 | PTGDR2 (0.42) | PTGDR2MTNR1AMTNR1BTBXA2RPTGDR | |
| SCHEMBL1887084 | 0.88 | PTGDR2 (0.43) | PTGDR2RORCXIAPMTNR1AMTNR1B | |
| SCHEMBL1879708 | 0.88 | PTGDR2 (0.42) | PTGDR2RORCXIAPMTNR1AMTNR1B | |
| SCHEMBL1875281 | 0.88 | PTGDR2 (0.42) | PTGDR2RORCXIAPMTNR1AMTNR1B | |
| SCHEMBL1875284 | 0.88 | PTGDR2 (0.42) | PTGDR2RORCXIAPMTNR1AMTNR1B | |
| SCHEMBL1879437 | 0.86 | MTNR1A (0.49) | PTGDR2RORCXIAPMTNR1AMTNR1B | |
| SCHEMBL1874237 | 0.86 | PTGDR2 (0.43) | PTGDR2RORCXIAPMTNR1AMTNR1B | |
| SCHEMBL12636982 | 0.86 | PTGDR2 (0.41) | PTGDR2RORCXIAPMTNR1AMTNR1B | |
| SCHEMBL1880816 | 0.85 | PTGDR2 (0.41) | PTGDR2RORCXIAPMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935722-B2 | Tetrahydrocarbazole derivatives useful as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935722-B2 | Tetrahydrocarbazole derivatives useful as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935722-B2 | Tetrahydrocarbazole derivatives useful as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| EP-1902026-B1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) | LILLY CO ELI (US) | 2010-02-17 | — | — | EP | disclosed |
| EP-1902026-B1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) | LILLY CO ELI (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | CELLECTIS (FR) | 2010-01-28 | — | — | US | disclosed |
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | CELLECTIS (FR) | 2010-01-28 | — | — | US | disclosed |
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | CELLECTIS (FR) | 2010-01-28 | — | — | US | disclosed |
| EP-1902026-A2 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) | ELI LILLY AND COMPANY (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007002181-A2 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) | ELI LILLY AND COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | AR, SHBG, CYP17A1 | PTGDR2 437/4885RORC 886/4885XIAP 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.